PP405: the molecule that might wake up your dormant follicles (what the science actually says in 2026)

The subject is lighting up forums, clinics and even Time magazine, which ranked PP405 among its best inventions of 2025. No surprise there. Most treatments protect what you already have. Finasteride blocks the guilty hormone. Minoxidil extends the growth phase. But none of them brings a sleeping follicle back to life. That is exactly what PP405 aims at, by a route nobody had dared to take: the metabolism of the cell, not the hormones.

A phase 3 trial is announced for 2026. So let us separate fact from fantasy. Here, with no hype and no inflated promises, is everything the science says today about PP405: its mechanism, its results, its timeline, its limits, and what you can actually do while you wait.

So what exactly is PP405?

PP405 is a small molecule applied locally to the scalp. Not a hormone. Not an injection. Not a tablet. A gel, once a day, and that is it.

It came out of the labs at UCLA, in California. Three scientists from the university, Bill Lowry, Heather Christofk and Michael Jung, founded Pelage Pharmaceuticals in 2018 to take it into the clinic. Nearly ten years of basic research came first, then serious money: more than 30 million dollars to start, led by Google Ventures, followed by a 120 million dollar raise in October 2025. When investors of that calibre put big money behind a hair gel, the mechanism tends to hold up.

Its angle of attack has nothing to do with the classic drugs. Hereditary baldness, also called androgenetic alopecia, does not kill your follicles in one go. It sends them to sleep. They shrink, miniaturise, then slip into prolonged dormancy. The hair becomes thin, short, almost see-through. And then one day, nothing comes out at all. But the follicle is often still there, tucked away, alive.

It is precisely these sleeping follicular stem cells that PP405 goes after. The goal: wake them up and restart the growth cycle. This is a regenerative approach, in the same spirit as regenerative hair medicine, which tries to stimulate follicles rather than just slow their decline.

Why this could be a real shift

To understand the excitement, you have to look at the current picture. Since minoxidil and finasteride arrived in the 1980s and 1990s, nothing fundamentally new has come along. We refine, we combine, we optimise. But the principle stays the same: defend the hair that is left.

PP405 offers something else. Not defend, but regenerate. Wake up follicles you thought were gone. If the science holds up at scale, it would move the line of what can be treated without a scalpel. Not a replacement for a transplant, as we will see. But one more string to the bow, and a new one.

Three things set PP405 apart from the dozens of pseudo-miracle hair products that come round every year:

• A precise, published biological target, validated by basic research before a single marketing promise.
• Clinical results measured in humans, not just in mice.
• A remarkable safety profile, with no passage into the bloodstream.

That is why serious dermatologists are watching it closely. Now it has to deliver beyond the trial.

The mechanism: a story about fuel, not hormones

Here is the point that changes everything. PP405 does not touch androgens at all. It works on the internal fuel of the follicle’s stem cells. To grasp the idea, you have to step inside the cell for a moment.

Waking a cell through its energy

Every hair follicle holds stem cells. When they are active, they make hair. When they are dormant, the follicle rests. And the UCLA research put its finger on something surprising: what wakes these cells up is a shift in metabolism. More precisely, a rise in lactate inside the cell.

Lactate is that by-product your muscles make under strain, the one that gives the burning feeling when you push hard. Inside the follicle it plays a completely different part: a start signal. Plenty of lactate, and the stem cell flips into growth mode, the phase known as anagen. Little lactate, and it stays asleep, the telogen phase. The lactate level is, in a sense, the switch between rest and growth.

The PP405 sleight of hand

The molecule locks what are called the mitochondrial pyruvate carriers (the MPC1 and MPC2 gates of the cell’s power plant, the mitochondrion). In plain terms, PP405 closes two doors through which fuel normally entered the mitochondrion.

With those doors shut, pyruvate builds up outside. An enzyme, lactate dehydrogenase (LDH), then converts it into lactate. The cascade that follows: lactate levels climb, glycolysis speeds up, the stem cell gets its start signal and goes back to work. The follicle flips back into growth mode.

It is elegant. And it sits at the opposite end from DHT blockers, which go after the hormonal cause of hair loss. Where DHT acts like a weedkiller smothering your follicles, PP405 plays the metabolic kick. Two opposing philosophies. And that is what opens the door to combining them one day, rather than pitting them against each other.

What the clinical trials actually say

Now for the numbers. This is where credibility is won or lost, and this is where PP405 stands apart from the run of the mill.

Phase 1: proof through biology

Before counting any hairs, the researchers wanted certainty: does the gel really wake the cells up? Phase 1, focused on safety, gave the answer. In just seven days, PP405 produced a statistically significant increase in stem cell activation inside the follicle, measured in particular through Ki67, a standard marker of cell proliferation. The translation: what they saw in the lab held true in humans. The dormant cells got back to work. First box ticked.

Phase 2a: 78 patients, clear results

The phase 2a trial was randomised, double blind, with a placebo group, the gold standard for rigour. In total, 78 adults with androgenetic alopecia, men and women, with a real range of skin tones and hair textures. Each one applied a PP405 gel dosed at 0.05%, once a day, for 4 weeks, with follow up extended to the twelfth week.

The standout result: around 31% of the men with the most advanced loss gained more than 20% in hair density by the eighth week, which was four weeks after stopping treatment. In the placebo group, nobody. And the detail that really matters: terminal hair grew in areas that had been bare. Not fine fuzz, not a simple thickening of existing hair. New hair, thick, where there had been none.

Note the speed too. A visible response in eight weeks, where minoxidil and finasteride often need six to twelve months to show anything at all. It is one of the most striking arguments for PP405.

Phase 2b: already wrapped up

Pelage did not wait. A phase 2b ran in late 2025, as an open label extension with three months of treatment this time instead of four weeks. The idea: see what longer exposure produces, closer to real use. The full data is expected at a medical congress in 2026. Worth watching very closely, because this longer view is what will tell us whether the effect strengthens over time.

Safety: probably the strongest point

The trial ticked every safety box. No detectable systemic absorption in the blood: the molecule stays where you put it, on the scalp, and does not circulate through the body. No hormonal disruption, no systemic side effects, good general tolerance.

This is a weighty argument, especially against the fears that stick to some oral treatments. A topical product that does not get into the blood, by design, clears away much of the worry about libido or mood that you sometimes hear linked to finasteride. That is reassuring, naturally.

PP405 against current treatments

To place PP405, nothing beats a side by side comparison with what already exists and has proven itself.

The table says the essential. PP405 targets ground that nobody else occupies: the regeneration of dormant follicles. But on the other side, minoxidil and finasteride have decades of track record behind them and immediate availability. That is the whole gap between a brilliant promise and a safe bet. One does not cancel the other. The day PP405 is approved, it will most likely complement these treatments rather than replace them, combining the metabolic wake up with the hormonal block.

PP405 against the other regenerative innovations

PP405 is not moving forward alone. Several lines of work are trying to go beyond simply defending what exists. Quickly, a tour of the field.

• Verteporfin. A molecule first used in ophthalmology, studied at Stanford for its effect of healing without fibrosis (by inhibiting the YAP protein). In hair transplants, the hope is twofold: reduce micro scarring and perhaps restart follicles. Still very experimental in humans for baldness.
• Exosomes. Tiny vesicles from stem cells, packed with growth factors, that pass repair signals to the follicle. Already used in clinics as a stimulating treatment, they are still under rigorous evaluation. Dr Cinik offers them, in fact, as an exosome treatment.
• Hair cloning. The distant holy grail: multiply your own follicles in a lab to reimplant them with no limit on the donor area. Companies like Stemson Therapeutics and HairClone are working on it. But this remains research, with no credible short term timeline.

Among all this, PP405 has a clear head start: it is the only one to show measured clinical results in humans and a dated phase 3 timeline. The other lines are fascinating, but further down the road.

Timeline, expectations and a word of caution

Let us be honest about the timing, because this is where a lot of sites mislead you.

Phase 3, the decisive step before any commercial launch, is set to start in 2026, running for about a year. It should impose one notable condition on participants: a stop of around six months on current treatments (minoxidil, finasteride) before entering the study, to isolate the effect of PP405 itself. Pelage will also present its work at the American Academy of Dermatology (AAD) meeting in March 2026, in Denver, during a session on emerging treatments targeting dormant follicles.

But let us keep a cool head. A phase 2a on 78 people is still a modest sized study, with a short track record (four weeks of treatment). The famous 31% applies to a specific subgroup: men with advanced loss. Nothing universal, then. And to date, the results have not yet been published in a peer reviewed scientific journal, nor accompanied by before and after photos shared with the public. It is phase 3, run on hundreds of patients over a longer period, that will tell us whether the effect holds over time and at scale.

In short: regulatory approval is not expected before 2027 to 2029, in the best case. PP405 is a serious and genuinely new line of research, not a product on the pharmacy shelf tomorrow morning.

Watch out for scams. PP405 is not available for sale, anywhere, full stop. Any site claiming to sell it to you, under this name or another, is deceiving you. The only legitimate access today is through the official clinical trials. Be extremely wary.

This molecule joins the short list of new baldness drugs to watch, alongside clascoterone, another promising treatment from recent years.

Who could benefit, and who could not

Here is the truth too often forgotten in the excitement. A sleeping follicle can be woken. A dead follicle, never. No topical treatment grows a hair back where the follicle has fully disappeared and scarred over. PP405 will be no exception.

That is where all the nuance lies. PP405 targets miniaturised but still living follicles, typical of the intermediate stages.

The potential good candidates:

• People at the early to moderate stages of loss, where the follicle is still breathing.
• Intermediate stages of the Norwood-Hamilton scale in men.
• Intermediate stages of the Ludwig scale in women, bearing in mind that the trial included women, which is rare and encouraging.

Those for whom PP405 will do nothing:

• Complete baldness settled in for a long time, where the stem cell reserve has gone.
• Smooth, shiny, scarred areas with no residual follicle at all.
• Scarring alopecias of other origins, which destroy the follicle itself.

No cell, no possible wake up. Understanding the hair cycle helps you grasp why timing matters so much: you have to act while the follicle is still there. That is also why waiting for PP405 with your arms folded for years can be a bad idea. While you wait, follicles that could have been saved finish dying out.

FAQ: your questions about PP405

Is PP405 available in the UK or anywhere else?

No. PP405 is still in the clinical trial phase and is not sold anywhere in the world. No pharmacy and no serious site can supply it in 2026.

When will it be on sale?

If phase 3 confirms the results and the regulators give the green light, a market launch would not be expected before 2027 to 2029 at the earliest. And only if everything goes well.

Will PP405 replace a hair transplant?

No, the two follow different logics. PP405 wakes up follicles that are still alive. A transplant redeploys follicles where none are left at all. On a fully bare area, PP405 has nothing to wake.

Are there side effects?

The trials run so far show good tolerance, with no passage of the molecule into the blood and no hormonal effect. But the track record is short: it is phase 3, longer, that will really pin down the safety profile over time.

Does PP405 work in women?

The phase 2a trial included men and women, which is rare and promising. The most striking results, though, were in men with advanced loss. To be confirmed.

Can PP405 be combined with minoxidil or finasteride?

In theory their mechanisms are complementary (metabolic wake up on one side, hormonal block on the other). But no study has validated this yet, and phase 3 will specifically require stopping these treatments to measure the effect of PP405 on its own.

What to do in practice today

PP405 opens up an exciting path. But in 2026, you have to work with what already exists and has proven itself. And what works depends first on your stage of loss.

For early or moderate loss, the validated medical treatments keep their full place, as we set out in our guide to hair loss treatments that actually work. Alongside them, the regenerative treatments offered in the clinic already stimulate weakened follicles, in the same spirit as PP405, but available now. PRP, included in every transplant package, boosts microcirculation. Exosomes deliver hundreds of growth factors. Mesotherapy feeds the scalp deep down.

And when the follicle has gone on certain areas, the only lasting answer is still a transplant. Today’s techniques, whether Sapphire FUE or DHI, redeploy your own follicles where they are needed, for a natural and permanent result. Dr Emrah Cinik, with more than 20 years of experience and protocols in line with ISHRS standards, examines each scalp to point towards the right approach. Sometimes it is medical, sometimes it is a hair transplant in Turkey, often it is a combination of both.

The real advice? Do not bet everything on a molecule still in trials. Act on what is within your reach while your follicles are still there to save. Do feel free to ask for a personalised free consultation. It is the best way to see clearly where you actually stand, without waiting until 2029.

Scientific references

Flores, A., Schell, J., Krall, A. S., Jelinek, D., Miranda, M., Grigorian, M., Braas, D., White, A. C., Zhou, J. L., Graham, N. A., Graeber, T., Seth, P., Evseenko, D., Coller, H. A., Rutter, J., Christofk, H. R., & Lowry, W. E. (2017). Lactate dehydrogenase activity drives hair follicle stem cell activation. Nature Cell Biology, 19(9), 1017-1026. https://pubmed.ncbi.nlm.nih.gov/28812580/

Liu, X., Wang, Y., Christofk, H. R., Lowry, W. E., & Jung, M. E. (2021). Development of novel mitochondrial pyruvate carrier inhibitors to treat hair loss. Journal of Medicinal Chemistry, 64(4), 2046-2063. https://pubmed.ncbi.nlm.nih.gov/33534563/

Pelage Pharmaceuticals. (2025, 17 juin). Pelage Pharmaceuticals announces positive phase 2a clinical trial results for PP405 in regenerative hair loss therapy [Communiqué de presse]. https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-positive-phase-2a-clinical-trial-results-for-pp405-in-regenerative-hair-loss-therapy/

Pelage Pharmaceuticals. (2025, octobre). Pelage Pharmaceuticals announces 120 million Series B financing to advance regenerative medicine treatments for hair loss [Communiqué de presse]. https://pelagepharma.com/press-releases/pelage-pharmaceuticals-announces-120-million-series-b-financing-to-advance-regenerative-medicine-treatments-for-hair-loss/

Pelage Pharmaceuticals. (2026). Pelage Pharmaceuticals PP405 and its impact on follicular regeneration to be presented at the American Academy of Dermatology (AAD) annual meeting 2026 [Communiqué de presse]. https://pelagepharma.com/press-releases/pelage-pp405-aad-2026/

National Library of Medicine. (2024). A study to evaluate the safety, pharmacokinetics and efficacy of PP405 in androgenetic alopecia (NCT06393452). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06393452

Ho, C. H., Sood, T., & Zito, P. M. (2024). Androgenetic alopecia. StatPearls. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK430924/

Dermatology Times. (2025). Pelage’s PP405 demonstrates efficacy in phase 2a trial for androgenetic alopecia. https://www.dermatologytimes.com/view/pelage-s-pp405-demonstrates-efficacy-in-phase-2a-trial-for-androgenetic-alopecia